Test Price
1,600 AED✅ Home Collection Available
ONCOPRO® LUNG BASIC PANEL Test in UAE | 1600 AED | DHA Approved
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – archival FFPE block transported at ambient temperature with completed Chromosome & FISH Requisition Form (Form 17).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by experienced specialists.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The ONCOPRO LUNG BASIC PANEL is a targeted molecular test that analyzes key genetic alterations in lung cancer tissue using dual-platform FISH and Sanger sequencing, enabling oncologists to select precise targeted therapies. By detecting EGFR, KRAS, ALK rearrangements, and ROS1 mutations, it delivers actionable insights within 3 business days using a single FFPE tumor block with at least 10% tumor cell content.
| Feature | ONCOPRO LUNG BASIC PANEL | Standard IHC / Single-Gene PCR |
|---|---|---|
| Precision | Multi-gene (FISH + Sanger) – covers EGFR, KRAS, ALK, ROS1 | Single-gene (e.g., EGFR PCR) – limited actionable information |
| Method | FISH + Sanger Sequencing (dual-platform orthogonal confirmation) | IHC or PCR only |
| Speed | 3 business days (Mon/Thu collection, Fri/Tue report) | 2–3 days |
| Price | 1,600 AED | ~900 AED (variable by gene and platform) |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor | Specialist Diagnostic Radiology | DHA Registration ID: 61713011: “Accurate molecular profiling of lung cancer dictates the success of targeted therapy. This panel consolidates four essential biomarkers into a single workflow, reducing tissue depletion and turnaround delay. However, results must always be correlated with histology, imaging, and the patient’s performance status. A multidisciplinary review of the full report is strongly advised before initiating any treatment regimen.”
Medication Advisory
Do not alter or discontinue any prescribed oncology medications without direct consultation with your treating physician. This test provides molecular guidance but does not replace comprehensive clinical judgment.
Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that all biopsy and tissue retrieval procedures meet the highest standards of care.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Biopsy sample with less than 10% tumor cell content (may yield inconclusive results).
- Specimens not submitted as formalin-fixed paraffin-embedded (FFPE) block.
- Missing or incomplete Chromosome & FISH Analysis Requisition Form (Form 17).
- Unfixed or fresh tissue specimens.
Emergency Red Flags After Biopsy
- Severe chest pain or shortness of breath.
- Heavy or persistent bleeding from the biopsy site.
- Signs of infection: fever, chills, or swelling at the site.
- Any sudden neurological changes.
Patient FAQ & Clinical Guidance
1. What is the ONCOPRO LUNG BASIC PANEL and who should order it?
The ONCOPRO LUNG BASIC PANEL detects EGFR, KRAS, ALK, and ROS1 mutations in lung cancer tissue, guiding targeted therapy selection. It is designed for patients newly diagnosed with non‑small cell lung cancer (NSCLC) and is ordered by medical oncologists, pulmonologists, or surgical pathologists to inform precision oncology decisions. The test requires an FFPE block with at least 10% tumor nuclei.
2. How is the test performed and what sample is required?
A formalin-fixed paraffin-embedded (FFPE) tumor tissue block with at least 10% tumor cells is required. The sample is obtained via biopsy or surgical resection, fixed in formalin, and embedded in paraffin. The block must be shipped at room temperature along with a duly completed Chromosome & FISH Analysis Requisition Form (Form 17). No special fasting or medication adjustments are needed prior to tissue collection.
3. What is the turnaround time and how do I receive results?
Results are typically available within 3 business days. Samples are accepted on Monday or Thursday by 9 AM; reports are delivered on Friday or Tuesday. A detailed digital report is shared securely, and our clinical team offers a complimentary telephonic consultation to explain the findings and recommend next steps.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: All patient data and test results are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic and clinical information is encrypted, access-controlled, and used solely for diagnostic and treatment guidance purposes.
Clinical & Logistical Metadata
| Test Name | ONCOPRO® LUNG BASIC PANEL (EGFR, KRAS, ALK, ROS1) |
| Price (AED) | 1,600 AED |
| Turnaround Time | 3 Business Days (Mon/Thu collection, Fri/Tue report) |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block – Archival Specimen. Secure Medical Courier Solid Tissue Specimen Retrieval. |
| Methodology Used | FISH + Sanger Sequencing (dual-platform orthogonal confirmation) |
| ICD-10-CM Code | C34.90 (Malignant neoplasm of unspecified part of unspecified bronchus or lung) |
| LOINC Code | 21631-8 (EGFR gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians